Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Price, News & Analysis

DICE Therapeutics logo

About DICE Therapeutics Stock (NASDAQ:DICE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$47.55
$47.55
50-Day Range
$46.62
$47.55
52-Week Range
$15.08
$47.90
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Remove Ads
Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Stock News Headlines

Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
Buy, Sell, Or Hold LLY Stock At $850?
See More Headlines

DICE Stock Analysis - Frequently Asked Questions

DICE Therapeutics, Inc. (NASDAQ:DICE) posted its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77.

DICE Therapeutics (DICE) raised $160 million in an IPO on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that DICE Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Honeywell International (HON), HubSpot (HUBS), Walt Disney (DIS) and Bank of America (BAC).

Company Calendar

Last Earnings
11/12/2021
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
71
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-83,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.13 million
Price / Cash Flow
N/A
Book Value
$10.86 per share
Price / Book
4.38

Miscellaneous

Free Float
45,392,000
Market Cap
$2.27 billion
Optionable
Not Optionable
Beta
1.03
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:DICE) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners